New research reveals a promising nanoparticle-based nasal therapy targeting immune system rebalance for allergic rhinitis. Bryostatin-1, delivered through specially engineered lipid nanoparticles, shows potential in reducing allergic responses and boosting mucosal defense.
Anionic LNPs, in particular, enhance bryo-1 delivery to B cells, promoting IgA production and suppressing IgE expression. Laboratory tests indicate that even low doses can increase salivary IgA levels.
While results are positive in preclinical models, human trials are necessary to verify safety and efficacy. If successful, this therapy could revolutionize allergic rhinitis management.